Paid Clinical Trials District of Columbia
Discover 820 paid clinical trials in District of Columbia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Sponsor:
AbbVie
Location:
Code:
NCT04064827
Conditions
Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Eligibility Criteria
Sex: All
Age: 0 - 9
Healthy Volunteers: Not accepted
Interventions
Paricalcitol
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Sponsor:
Takeda
Location:
Code:
NCT04844073
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAK-186
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Sponsor:
American Thrombosis and Hemostasis Network
Location:
Code:
NCT04647227
Conditions
Hemophilia A With Inhibitor
Hemophilia B With Inhibitor
Eligibility Criteria
Sex: All
Age: 12 - 70+
Healthy Volunteers: Not accepted
Interventions
coagulation factor VIIa [recombinant]-jncw
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor:
Sanofi
Location:
Code:
NCT06141473
Conditions
Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Frexalimab
Teriflunomide
Placebo infusion
Placebo tablet
MRI contrast-enhancing agents
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Sponsor:
Fujifilm Pharmaceuticals U.S.A., Inc.
Location:
Code:
NCT05318573
Conditions
Advanced Urothelial Carcinoma
Advanced Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
FF-10832
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Sponsor:
Allogene Therapeutics
Location:
Code:
NCT04696731
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
ALLO-316
ALLO-647
Fludarabine
Cyclophosphamide
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
Sponsor:
Carelon Research
Location:
Code:
NCT05268094
Conditions
Congenital Heart Disease in Children
Eligibility Criteria
Sex: All
Age: 1 - 30
Healthy Volunteers: Not accepted
Interventions
Ductal Arterial Stent
Systemic-to-Pulmonary Artery Shunt
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06607627
Conditions
Generalized Myasthenia Gravis
gMG
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Gefurulimab
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02852031
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility Criteria
Sex: All
Age: 0 - 15
Healthy Volunteers: Not accepted
Interventions
Collaborative Learning Network